FUJIFILM Biotechnologies Enhances UK Biomanufacturing with Major Expansion

In a significant boost to the UK’s biomanufacturing sector, FUJIFILM Biotechnologies has inaugurated its expanded facility in Teesside, following a £400 million investment. The new development enhances the company’s capacity to produce and develop innovative medicines and vaccines, heralding a new era of growth for the biologics and vaccine manufacturing sectors.

FUJIFILM Biotechnologies, a leading contract development and manufacturing organisation (CDMO), has taken a strategic leap by expanding its presence in Teesside. This development introduces the largest single-use biopharmaceutical CDMO facility in the UK, slated to operate in early 2026. The expansion brings advanced single-use bioreactors and a bioprocess innovation centre, positioning the UK as a pivotal player in the production of complex medicines for cancer, neurodegenerative diseases, and rare disorders. The investment is part of FUJIFILM’s broader vision to harmonise global operations through its kojoX™ modular approach, aligning closely with its facilities in Japan.

By doubling its lab footprint and enhancing GMP capabilities, the Teesside expansion solidifies FUJIFILM’s commitment to meeting global demand for innovative therapies. The project marks a critical advancement for the life sciences sector in the UK and showcases FUJIFILM’s pivotal role in driving biomanufacturing excellence. As the new facilities open doors, they promise to deliver unparalleled opportunities for pharmaceutical and biotechnology partners globally.